Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Ciclesonide in Adults With Mild-to-moderate COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with mild COVID-19 (NEWS scoring system 0-4)~* Patient within 7 days from symptom onset or Patient within 48 hous after laboratory diagnosis (SARS-CoV-2 RT-PCR)~Exclusion Criteria:~* Hypoxia (SaO2 \<95%)~* Unable to take oral medication~* Unable to use inhaler~* Pregnancy or breast feeding~* Immunocompromising conditions~* Moderate/severe renal dysfunction : creatinine clearance (CCL) \< 30 mL/min~* Moderate/severe liver dysfunction: AST or ALT \> 5 times upper normal limit~* Asthma or chronic obstructive lung disease

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Ciclesonide (Type: EXPERIMENTAL): Ciclesonide 320ug oral inhalation q12h for 14 days
- Control (Type: NO_INTERVENTION): Standard care without ciclesonide

Based on this trial design, predict the completion outcome and termination type (if applicable).